Details of the Drug

General Information of Drug (ID: DM14MAE)

• Drug Name: Pergolide
• Synonyms: Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1], [2]

• Therapeutic Class: Antiparkinson Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 314.5
  Topological Polar Surface Area (xlogp); 4.2
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• Chemical Identifiers:
  Formula: C19H26N2S
  IUPAC Name: (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
  Canonical SMILES: CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
  InChI: InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1
  InChIKey: YEHCICAEULNIGD-MZMPZRCHSA-N
• Cross-matching ID:
  PubChem CID: 47811
  ChEBI ID: CHEBI:63617
  CAS Number: 66104-22-1
  DrugBank ID: DB01186
  TTD ID: D04JCN

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Modulator	[3]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Modulator	[3]

Molecular Expression Atlas of This Drug

• The Studied Disease: Parkinson disease
• ICD Disease Classification: 8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D1 receptor (D1R)	DTT	DRD1	8.99E-01	-0.06	-0.3
Dopamine D2 receptor (D2R)	DTT	DRD2	2.20E-03	-0.51	-1.35

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pergolide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Pergolide when combined with OPC-34712.	Depression [6A70-6A7Z]	[24]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Pergolide and Esketamine.	Depression [6A70-6A7Z]	[25]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Pergolide when combined with ITI-007.	Insomnia [7A00-7A0Z]	[24]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Pergolide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[26]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Pergolide and Lasmiditan.	Migraine [8A80]	[27]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Pergolide and Flibanserin.	Mood disorder [6A60-6E23]	[28]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Pergolide when combined with Metoclopramide.	Nausea/vomiting [MD90]	[24]
Levomepromazine	DMIKFEL	Moderate	Additive CNS depression effects by the combination of Pergolide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[24]
Quetiapine	DM1N62C	Moderate	Antagonize the effect of Pergolide when combined with Quetiapine.	Schizophrenia [6A20]	[24]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Pergolide when combined with Aripiprazole.	Schizophrenia [6A20]	[24]
Iloperidone	DM6AUFY	Moderate	Antagonize the effect of Pergolide when combined with Iloperidone.	Schizophrenia [6A20]	[24]
Paliperidone	DM7NPJS	Moderate	Antagonize the effect of Pergolide when combined with Paliperidone.	Schizophrenia [6A20]	[24]
Molindone	DMAH70G	Moderate	Antagonize the effect of Pergolide when combined with Molindone.	Schizophrenia [6A20]	[24]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Pergolide when combined with Thiothixene.	Schizophrenia [6A20]	[24]
Amisulpride	DMSJVAM	Major	Additive CNS depression effects by the combination of Pergolide and Amisulpride.	Schizophrenia [6A20]	[25]
Asenapine	DMSQZE2	Moderate	Antagonize the effect of Pergolide when combined with Asenapine.	Schizophrenia [6A20]	[24]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Pergolide when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[29]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 48).
• [2] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [5] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [6] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [7] Clinical pipeline report, company report or official report of Lundbeck.
• [8] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [9] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [10] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [11] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [12] The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.
• [13] Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6.
• [14] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [15] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [16] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [17] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [18] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [20] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [21] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [22] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [23] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [24] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [25] Cerner Multum, Inc. "Australian Product Information.".
• [26] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [27] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [28] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [29] Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.